USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Sharp Life Science (eu) Limited

USPTO PatentsView assignee record — 52 granted patents across 19 technology areas, active 2017–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: B01L (CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE).

52
Total patents granted
19
CPC technology areas
17.4
Avg claims per patent
+320%
5-year filing velocity

The verdict

Sharp holds 52 US patents across 19 technology areas — rank #6,486 of 50,000 tracked assignees.

#6,486
of 50,000 US assignees by volume
Top 30%
by Innovation Score (42.7/100)
17.4
avg claims per patent
+320%
filing velocity, last 5 yrs

Portfolio overview

Sharp Life Science (EU) Limited has been granted 52 US utility patents between 2017 and 2024, placing Sharp Life Science (EU) Limited at rank #6,486 across all assignees tracked by PlainPatent. This portfolio spans 19 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.4 claims per patent with primary concentration in B01L (CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE). As a Foreign Corporation, Sharp Life Science (EU) Limited is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 42.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 42 grants, compared with 10 in the 2015–2019 window — a +320% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Sharp Life Science (EU) Limited's 17.4 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 19 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Sharp Life Science (EU) Limited against peers pursuing similar technology classes.

How does Sharp compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows Sharp holds 52 patents — placing it at rank #6,486 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

Sharp's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

43 Top 30% higher than 70% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). This entry sits in this band. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2024

051015 20172018201920202021202220232024 4
USPTO utility patent grants by year · 2017–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table
Sharp Life Science (EU) Limited patent grants by year, 2015–2025
Year Patents Granted Share of Period
2017 2 3.8%
2018 3 5.8%
2019 5 9.6%
2020 14 26.9%
2021 13 25.0%
2022 8 15.4%
2023 3 5.8%
2024 4 7.7%

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Velocity Accelerating

Where it ranks

Overall rank by patents

#6,486

Across all tracked assignees

Innovation Score

42.7 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Sharp Life Science (EU) Limited hold?
Sharp Life Science (EU) Limited holds 52 US granted patents filed between 2017 and 2024, spanning 19 technology areas.
What is Sharp Life Science (EU) Limited's Innovation Score?
Sharp Life Science (EU) Limited has an Innovation Score of 42.7 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Sharp Life Science (EU) Limited focus on?
Sharp Life Science (EU) Limited's top technology area is B01L (CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE) with 49 patents. The company has filed patents in 19 CPC subclasses total.
Is Sharp Life Science (EU) Limited's patent filing rate increasing or decreasing?
Sharp Life Science (EU) Limited's recent filing velocity is +320% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Sharp Life Science (EU) Limited's patents?
Sharp Life Science (EU) Limited's patents average 17.4 claims each. This falls within the standard range, providing solid legal coverage.
How is the Sharp Life Science (EU) Limited patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

How to use this portfolio

Sharp's 52 grants land it in the top 30% by Innovation Score — but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance — Sharp ranks #6,486 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in B01L — see who else leads that technology area. B01L leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity — not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Data sources used on this page
  • USPTO PatentsView — the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) — the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search — the official interface to verify the status of any individual patent. ppubs.uspto.gov